Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer
Shengwei Zhang, Jing Wang, Weichao Hu, Lijiao He, Qingyun Tang, Jie Li, Mengmeng Jie, Xinzhe Li, Cheng Liu, Qin Ouyang, Shiming Yang, Changjiang Hu
Shengwei Zhang, Jing Wang, Weichao Hu, Lijiao He, Qingyun Tang, Jie Li, Mengmeng Jie, Xinzhe Li, Cheng Liu, Qin Ouyang, Shiming Yang, Changjiang Hu
View: Text | PDF
Research Article Gastroenterology Oncology

RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer

  • Text
  • PDF
Abstract

Forkhead box M1 (FOXM1) plays a critical role in development physiologically and tumorigenesis pathologically. However, insufficient efforts have been dedicated to exploring the regulation, in particular the degradation of FOXM1. Here, the ON-TARGETplus siRNA library targeting E3 ligases was used to screen potential candidates to repress FOXM1. Of note, mechanism study revealed that RNF112 directly ubiquitinates FOXM1 in gastric cancer, resulting in a decreased FOXM1 transcriptional network and suppressing the proliferation and invasion of gastric cancer. Interestingly, the well-established small-molecule compound RCM-1 significantly enhanced the interaction between RNF112 and FOXM1, which further promoted FOXM1 ubiquitination and subsequently exerted promising anticancer effects in vitro and in vivo. Altogether, we demonstrate that RNF112 suppresses gastric cancer progression by ubiquitinating FOXM1 and highlight the RNF112/FOXM1 axis serves as both prognosis biomarker and therapeutic target in gastric cancer.

Authors

Shengwei Zhang, Jing Wang, Weichao Hu, Lijiao He, Qingyun Tang, Jie Li, Mengmeng Jie, Xinzhe Li, Cheng Liu, Qin Ouyang, Shiming Yang, Changjiang Hu

×

Figure 5

Ubiquitin ligase activity of RNF112 is responsible for FOXM1 ubiquitination and degradation.

Options: View larger image (or click on image) Download as PowerPoint
Ubiquitin ligase activity of RNF112 is responsible for FOXM1 ubiquitinat...
(A) Schematic graph of the RNF112-Mut lacking E3 ubiquitin ligase activity. (B) Co-IP assays between RNF112-WT (or RNF112-Mut) and FOXM1 in HEK293T cells. (C) Ubiquitination of FOXM1 was tested 48 hours after transfection with RNF112, RNF112-Mut, or EV in HEK293T cells in the presence of 10 μM MG132 for 8 hours. (D) Immunoblot analysis of FOXM1 expression in MGC803 and BGC823 cells with EV, RNF112-WT, and RNF112-Mut overexpression. (E and F) Quantitative reverse transcription–PCR analysis of FOXM1 downstream genes in MGC803 (E) and BGC823 (F) cells with EV, RNF112-WT, and RNF112-Mut overexpression (n = 3). (G and H) Colony-formation assays (G) and Transwell invasion assays (H) of the indicated stable overexpression cells (n = 3). Scale bar: 400 μm. Data are presented as mean ± SD. Statistical significance was calculated using 1-way ANOVA (E–H). *P < 0.05. Complete unedited blots are in the supplemental material.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts